Such antiproliferative effect could be explained in part by an impairment of AML cells’ viability since Annexin V-FITC/PI staining indicated that the peptide promoted apoptosis in HL-60 and OCI-AML3 cells and in primary cells from the majority of AML patients’ bone marrow samples (Figure 1B,C). Here, ANXA5 is linked to acute myeloid leukemia.